Nothing Special   »   [go: up one dir, main page]

EP1154771A4 - Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use - Google Patents

Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use

Info

Publication number
EP1154771A4
EP1154771A4 EP00910039A EP00910039A EP1154771A4 EP 1154771 A4 EP1154771 A4 EP 1154771A4 EP 00910039 A EP00910039 A EP 00910039A EP 00910039 A EP00910039 A EP 00910039A EP 1154771 A4 EP1154771 A4 EP 1154771A4
Authority
EP
European Patent Office
Prior art keywords
nitrosated
compositions
methods
proton pump
pump inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00910039A
Other languages
German (de)
French (fr)
Other versions
EP1154771A1 (en
Inventor
David S Garvey
L Gordon Letts
Sang William Tam
Tiansheng Wang
Stewart K Richardson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitromed Inc
Original Assignee
Nitromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitromed Inc filed Critical Nitromed Inc
Publication of EP1154771A1 publication Critical patent/EP1154771A1/en
Publication of EP1154771A4 publication Critical patent/EP1154771A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP00910039A 1999-02-26 2000-02-25 Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use Withdrawn EP1154771A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12211199P 1999-02-26 1999-02-26
US122111P 1999-02-26
PCT/US2000/002524 WO2000050037A1 (en) 1999-02-26 2000-02-25 Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use

Publications (2)

Publication Number Publication Date
EP1154771A1 EP1154771A1 (en) 2001-11-21
EP1154771A4 true EP1154771A4 (en) 2005-04-20

Family

ID=22400684

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00910039A Withdrawn EP1154771A4 (en) 1999-02-26 2000-02-25 Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use

Country Status (5)

Country Link
EP (1) EP1154771A4 (en)
JP (1) JP2002537336A (en)
AU (2) AU781133B2 (en)
CA (1) CA2362930C (en)
WO (1) WO2000050037A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002476D0 (en) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US20050020637A1 (en) * 2001-11-19 2005-01-27 Wolfgang-Alexander Simon Agents for the treatment of airway disorders
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
AU2003218726A1 (en) * 2002-03-14 2003-09-22 Altana Pharma Ag Use of proton pump inhibitors for the treatment of airway disorders
WO2003082854A1 (en) * 2002-03-29 2003-10-09 Zeria Pharmaceutical Co., Ltd. 1-n-aminobenzimidazole derivatives
JP2005537223A (en) * 2002-04-05 2005-12-08 ニトロメッド，インク． Nitric oxide donors, compositions and methods of use
CA2493618A1 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
FR2845917B1 (en) * 2002-10-21 2006-07-07 Negma Gild PHARMACEUTICAL COMPOSITION COMPRISING TENATOPRAZOLE AND ANTI-INFLAMMATORY
FR2845915B1 (en) * 2002-10-21 2006-06-23 Negma Gild USE OF TENATOPRAZOLE FOR THE TREATMENT OF GASTRO-OESOPHAGEAL REFLUX
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
TW200606163A (en) 2004-04-22 2006-02-16 Eisai Co Ltd Imidazopyridine compound
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
EP1915157A4 (en) 2005-08-02 2010-09-01 Nicox Sa Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
JP5075254B2 (en) 2011-01-07 2012-11-21 スノーデン株式会社 Lactic acid bacteria that suppress the production of gastric acid and gastrin
WO2021170093A1 (en) * 2020-02-26 2021-09-02 上海科技大学 Application of disulfiram in coronavirus resistance

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4420523A1 (en) * 1994-06-13 1995-12-14 Cassella Ag Treating and preventing SIRS, e.g. in shock, arthritis or peritonitis
WO1996024375A1 (en) * 1995-02-06 1996-08-15 Astra Aktiebolag New oral pharmaceutical dosage form
WO1997002021A1 (en) * 1995-07-05 1997-01-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors
US5599794A (en) * 1992-04-24 1997-02-04 Aktiebolaget Astra Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
US5610178A (en) * 1993-08-16 1997-03-11 Ciba-Geigy Corporation Macrolides and the use thereof
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
WO1998022118A1 (en) * 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid
WO1998054172A1 (en) * 1997-05-30 1998-12-03 Dr. Reddy's Research Foundation Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117268A (en) * 1991-10-22 1993-05-14 Yoshitomi Pharmaceut Ind Ltd Pyridine compound
PL182517B1 (en) * 1994-06-10 2002-01-31 Byk Gulden Lomberg Chem Fab Thiopyridines for fighting against heliobacter
CN1070488C (en) * 1994-06-10 2001-09-05 比克·古尔顿·劳姆贝尔格化学公司 Substituted arylalkylthioalkylthiopyridines for use in the control of helicobacter bacteria
NZ336034A (en) * 1996-12-20 2000-09-29 Byk Gulden Lomberg Chem Fab 3-nitro-imidazo[1,2-b]pyridazines substituted by alkylene-pyridine derivatives and medicaments

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599794A (en) * 1992-04-24 1997-02-04 Aktiebolaget Astra Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
US5610178A (en) * 1993-08-16 1997-03-11 Ciba-Geigy Corporation Macrolides and the use thereof
DE4420523A1 (en) * 1994-06-13 1995-12-14 Cassella Ag Treating and preventing SIRS, e.g. in shock, arthritis or peritonitis
WO1996024375A1 (en) * 1995-02-06 1996-08-15 Astra Aktiebolag New oral pharmaceutical dosage form
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
WO1997002021A1 (en) * 1995-07-05 1997-01-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors
WO1998022118A1 (en) * 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid
WO1998054172A1 (en) * 1997-05-30 1998-12-03 Dr. Reddy's Research Foundation Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0050037A1 *

Also Published As

Publication number Publication date
WO2000050037A1 (en) 2000-08-31
CA2362930C (en) 2010-10-05
AU781133B2 (en) 2005-05-05
CA2362930A1 (en) 2000-08-31
AU2005202553A1 (en) 2005-07-07
JP2002537336A (en) 2002-11-05
AU3219600A (en) 2000-09-14
EP1154771A1 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
IL150368A0 (en) Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
EP1534278A4 (en) Nitrosated proton pump inhibitors, compositions and methods of use
EP1109543A4 (en) Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
AU2003241464A1 (en) Compositions and methods using proton pump inhibitors
EP1154771A4 (en) Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
DE60009675D1 (en) COMPOSITION CONTAINING PROTON PUMP INHIBITORS
AU2001270070A1 (en) Nitrosated and nitrosylated taxanes, compositions and methods of use
AU3713600A (en) Nitrosated and nitrosylated prostaglandins, compositions and metods of use
AU8419201A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
ZA200501677B (en) Hydantoin derivatives and their use as TACE inhibitors.
AU2003293529A8 (en) Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
MXPA05011522A (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics.
PL350862A1 (en) Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or h2
GB9929552D0 (en) Compounds
AU2002366796A8 (en) Methods using proton pump inhibitors
IL150062A0 (en) Proton pump inhibitors
GB0114185D0 (en) Compounds
WO2005009928A3 (en) Preparation and use of alkylating agents
IL173914A0 (en) Proton pump inhibitor formulations, and methods of preparing and using such formulations
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
EP1673384A4 (en) Nitrosated glutamic acid compounds, compositions and methods of use
EP1539134A4 (en) Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP1379245A4 (en) 1, 4, 5, 6-tetrahydropyrazolo- 3, 4-c|-pyrid in-7-ones as factor xa inhibitors
AU2003261424A1 (en) Nitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of use
AU4937200A (en) Portable terminal

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010829

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050303

17Q First examination report despatched

Effective date: 20051123

17Q First examination report despatched

Effective date: 20051123

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 235/28 20060101ALI20080311BHEP

Ipc: A61P 1/04 20060101ALI20080311BHEP

Ipc: A61K 31/4184 20060101ALI20080311BHEP

Ipc: A61K 31/437 20060101AFI20080311BHEP

Ipc: A61K 31/4439 20060101ALI20080311BHEP

Ipc: C07D 401/12 20060101ALI20080311BHEP

Ipc: C07D 471/04 20060101ALI20080311BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080812